Physician profile
Priya Krishnamurthy
NPI 1821283631
$22,185.14
in general payments reported to CMS, 2019-2025
35 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,000 · 2020: $764 · 2021: $1,087 · 2022: $762 · 2023: $896 · 2024: $1,877 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,447 · Travel and Lodging: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,301.50 |
| Food and Beverage | $3,446.65 |
| Travel and Lodging | $824.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,873.90 | 2019-2025 | Tepezza, Evenity, Prolia |
| Ibsa Pharma INC. | $1,610.25 | 2019-2021 | |
| Medtronic Minimed, INC. | $1,442.99 | 2019 | |
| Radius Health, INC. | $539.11 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $371.23 | 2022-2025 | Korlym |
| Lilly USA, LLC | $324.38 | 2019-2025 | Zepbound, Mounjaro |
| Mannkind Corporation | $276.35 | 2020-2025 | |
| Novo Nordisk INC | $249.17 | 2019-2023 | Sogroya, Wegovy |
| Tandem Diabetes Care, INC. | $207.02 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Grt US Holding, INC. | $205.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $189.75 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $174.30 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $161.95 | 2023-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $141.63 | 2023-2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.90 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $136.43 | 2024-2025 | Crysvita |
| Dexcom, INC. | $127.84 | 2019-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $122.22 | 2023 | Strensiq |
| Abbott Laboratories | $119.26 | 2019-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $112.95 | 2022-2023 | Tepezza |
| Madrigal Pharmaceuticals | $99.64 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $98.87 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Astrazeneca Pharmaceuticals LP | $74.40 | 2019 | |
| Medtronic, INC. | $60.62 | 2021-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $54.81 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $49.60 | 2019-2024 | Omnipod |
| Abbvie INC. | $47.78 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.50 | 2022 | |
| Shire North American Group INC | $32.00 | 2019 | |
| Antares Pharma, INC. | $21.88 | 2025 | Xyosted |
| Pfizer INC. | $18.73 | 2023 | |
| Lundbeck LLC | $16.77 | 2022 | |
| Sequel Med Tech, LLC | $16.74 | 2025 | Twiist |
| Boston Scientific Corporation | $15.75 | 2025 | Watchman Flx |
| Nevro Corp. | $15.40 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Krishnamurthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.